SLDB

SEC source: 0000950170-25-086238 · ownership.xml · derivative · entry 1

Nagendran Sukumar · CIK 0001665124 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,500

Underlying: Common Stock · 77,500 shares

Expires 2035-06-12

F1 · derivative.exercise_date: This option was granted on June 12, 2025 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0000950170-25-086236 · ownership.xml · derivative · entry 1

Kahn Clare · CIK 0001849236 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,500

Underlying: Common Stock · 77,500 shares

Expires 2035-06-12

F1 · derivative.exercise_date: This option was granted on June 12, 2025 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0000950170-25-086232 · ownership.xml · derivative · entry 1

Sullivan Lynne Marie · CIK 0001727640 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,500

Underlying: Common Stock · 77,500 shares

Expires 2035-06-12

F1 · derivative.exercise_date: This option was granted on June 12, 2025 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0000950170-25-087881 · ownership.xml · derivative · entry 1

Keresty Georgia · CIK 0001773532 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,500

Underlying: Common Stock · 77,500 shares

Expires 2035-06-12

F1 · derivative.exercise_date: This option was granted on June 12, 2025 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0000950170-25-052050 · ownership.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,719

Underlying: Common Stock · 4,574 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 6, 2025 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Third Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 6, 2025 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Third Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

SEC source: 0000950170-25-052050 · ownership.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,546

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert to common stock on a one-for-one basis.

SEC source: 0000950170-25-038706 · ownership.xml · nonDerivative · entry 1

Kahn Clare · CIK 0001849236 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,960

SEC source: 0000950170-25-025011 · ownership.xml · derivative · entry 2

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

BCLS SB Investco, LP · CIK 0001728056 · 10% owner

Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner

Bain Capital Life Sciences Fund II, L.P. · CIK 0001773187 · 10% owner

Bain Capital Life Sciences Investors II, LLC · CIK 0001796155 · 10% owner

BCLS II Investco, LP · CIK 0001818893 · 10% owner

BCLS II Investco (GP), LLC · CIK 0001819101 · 10% owner

BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner

BCLS II Equity Opportunities, LP · CIK 0001814474 · 10% owner

BCLS II Equity Opportunities GP, LLC · CIK 0002008174 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 6,444,170

Underlying: Common Stock · 6,444,170 shares

Expires not disclosed

F1 · kind: On February 19, 2025, BCLS II Investco, LP ("BCLS II Investco") purchased 1,000,000 shares of the Issuer's common stock and a pre-funded warrant to purchase 6,444,170 shares of the Issuer's common stock at a purchase price of $4.03 and $4.029, respectively, in an underwritten public offering (the "February 2025 Underwritten Offering").

F2 · derivative.exercise_date: The pre-funded warrant cannot be exercised if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated with the holder for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's common stock then outstanding immediately following such exercise.

F3 · derivative.expiration_date: The pre-funded warrant does not expire.

F2 · derivative.underlying_shares: The pre-funded warrant cannot be exercised if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated with the holder for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's common stock then outstanding immediately following such exercise.

F5 · ownership.nature: Represents a pre-funded warrant to purchase 6,444,170 shares of the Issuer's common stock held directly by BCLS II Investco, after giving effect to the closing of the February 2025 Underwritten Offering.

F8 · ownership.nature: BCLS II Investco (GP), LLC ("BCLS II Investco GP"), whose managing member is BCLS Fund II, is the general partner of BCLS II Investco. As a result, each of BCLSI II, BCLS Fund II and BCLS II Investco GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Investco. Each of BCLSI II, BCLS Fund II and BCLS II Investco GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F11 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the general partner of BCLSP, (ii) is the manager of BCLSI II and (iii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

SEC source: 0000950170-25-025011 · ownership.xml · nonDerivative · entry 1

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

BCLS SB Investco, LP · CIK 0001728056 · 10% owner

Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner

Bain Capital Life Sciences Fund II, L.P. · CIK 0001773187 · 10% owner

Bain Capital Life Sciences Investors II, LLC · CIK 0001796155 · 10% owner

BCLS II Investco, LP · CIK 0001818893 · 10% owner

BCLS II Investco (GP), LLC · CIK 0001819101 · 10% owner

BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner

BCLS II Equity Opportunities, LP · CIK 0001814474 · 10% owner

BCLS II Equity Opportunities GP, LLC · CIK 0002008174 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 5,034,582

F1 · kind: On February 19, 2025, BCLS II Investco, LP ("BCLS II Investco") purchased 1,000,000 shares of the Issuer's common stock and a pre-funded warrant to purchase 6,444,170 shares of the Issuer's common stock at a purchase price of $4.03 and $4.029, respectively, in an underwritten public offering (the "February 2025 Underwritten Offering").

F4 · ownership.nature: Represents 528,660 shares of the Issuer's common stock held directly by BCLS SB Investco, LP ("BCLS SB"), 267,257 shares of the Issuer's common stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), 3,301,955 shares of the Issuer's common stock held directly by BCLS II Investco, 904,160 shares of the Issuer's common stock held directly by BCLS II Equity Opportunities, LP ("BCLS II Equity") and 32,550 shares of the Issuer's common stock held directly by BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II Investco, BCLS SB, BCLS Fund II and BCLS II Equity, the "Bain Capital Life Sciences Entities"), after giving effect to the closing of the February 2025 Underwritten Offering.

F6 · ownership.nature: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS SB. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS SB. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F7 · ownership.nature: Bain Capital Life Sciences Investors II, LLC ("BCLSI II") is the general partner of BCLS Fund II. As a result, BCLSI II may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund II. BCLSI II disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F8 · ownership.nature: BCLS II Investco (GP), LLC ("BCLS II Investco GP"), whose managing member is BCLS Fund II, is the general partner of BCLS II Investco. As a result, each of BCLSI II, BCLS Fund II and BCLS II Investco GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Investco. Each of BCLSI II, BCLS Fund II and BCLS II Investco GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F9 · ownership.nature: BCLS II Equity Opportunities GP, LLC ("BCLS II Equity GP"), whose manager is BCLS Fund II, is the general partner of BCLS II Equity. As a result, each of BCLSI II, BCLS Fund II and BCLS II Equity GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Equity. Each of BCLSI II, BCLS Fund II and BCLS II Equity GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F10 · ownership.nature: Boylston Coinvestors, LLC is the general partner of BCIPLS.

F11 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the general partner of BCLSP, (ii) is the manager of BCLSI II and (iii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

SEC source: 0001062993-25-003153 · form4.xml · nonDerivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 11,833,539

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager to the Master Fund. Mr. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001415889-25-005059 · form4-02212025_090218.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 3,722,085

Underlying: Common Stock · 3,722,085 shares

Expires not disclosed

F1 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F1 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0000902664-25-001114 · ownership.xml · nonDerivative · entry 1

Adage Capital Management, L.P. · CIK 0001535978 · 10% owner

Atchinson Robert · CIK 0001403404 · 10% owner

Gross Phillip · CIK 0001403413 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 4,248,084

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.22 to $7.75, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F2 · ownership.nature: The securities to which this filing relates are held directly by Adage Capital Partners, L.P., a Delaware limited partnership ("ACP"). Adage Capital Management, L.P., a Delaware limited partnership ("ACM"), serves as the investment manager of ACP and as such has discretion over the portfolio securities held by ACP. Robert Atchinson and Phillip Gross are the managing members of (i) Adage Capital Advisors, L.L.C., a Delaware limited liability company, managing member of Adage Capital Partners GP, L.L.C., a Delaware limited liability company, general partner of ACP and (ii) Adage Capital Partners LLC, a Delaware limited liability company, general partner of ACM.

F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except as to such extent of such Reporting Person's pecuniary interest in the securities, if any.

SEC source: 0000950170-25-022199 · ownership.xml · nonDerivative · entry 2

Ganot Ilan · CIK 0001727460 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Wife

Disclosed balance after: 14,839

F3 · kind: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot.

F3 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot.

SEC source: 0000950170-25-022206 · ownership.xml · nonDerivative · entry 2

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,281

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan.

SEC source: 0000950170-25-022203 · ownership.xml · nonDerivative · entry 2

Brooks Gabriel · CIK 0001997809 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,812

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.

SEC source: 0000950170-25-022201 · ownership.xml · nonDerivative · entry 2

Herzich Paul · CIK 0001954991 · Chief Technology Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,388

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Herzich on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Herzich.

SEC source: 0000950170-25-022202 · ownership.xml · nonDerivative · entry 2

Tan Kevin · CIK 0001884056 · CFO & Treasurer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,250

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Tan on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Tan.

SEC source: 0000950170-25-022196 · ownership.xml · nonDerivative · entry 2

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,789

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton.

SEC source: 0000950170-25-022200 · ownership.xml · nonDerivative · entry 2

Cumbo Alexander · CIK 0001685994 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,717

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Cumbo.

SEC source: 0000950170-25-022199 · ownership.xml · derivative · entry 5

Ganot Ilan · CIK 0001727460 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Wife

Disclosed balance after: 14,583

Underlying: Common Stock · 4,861 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F5 · derivative.exercise_date: On February 13, 2024 (the "Grant Date") Ms. Ganot was granted 19,444 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date.

F5 · derivative.expiration_date: On February 13, 2024 (the "Grant Date") Ms. Ganot was granted 19,444 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date.

SEC source: 0000950170-25-022199 · ownership.xml · nonDerivative · entry 1

Ganot Ilan · CIK 0001727460 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Wife

Disclosed balance after: 16,550

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000950170-25-022206 · ownership.xml · derivative · entry 3

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,375

Underlying: Common Stock · 8,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000950170-25-022206 · ownership.xml · nonDerivative · entry 1

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,360

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

SEC source: 0000950170-25-022203 · ownership.xml · derivative · entry 3

Brooks Gabriel · CIK 0001997809 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,813

Underlying: Common Stock · 10,937 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000950170-25-022203 · ownership.xml · nonDerivative · entry 1

Brooks Gabriel · CIK 0001997809 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,068

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

SEC source: 0000950170-25-022201 · ownership.xml · derivative · entry 3

Herzich Paul · CIK 0001954991 · Chief Technology Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,563

Underlying: Common Stock · 7,187 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000950170-25-022201 · ownership.xml · nonDerivative · entry 1

Herzich Paul · CIK 0001954991 · Chief Technology Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,076

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

SEC source: 0000950170-25-022202 · ownership.xml · derivative · entry 3

Tan Kevin · CIK 0001884056 · CFO & Treasurer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,875

Underlying: Common Stock · 10,625 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The restricted stock units were granted on February 13, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The restricted stock units were granted on February 13, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000950170-25-022202 · ownership.xml · nonDerivative · entry 1

Tan Kevin · CIK 0001884056 · CFO & Treasurer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,414

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

SEC source: 0000950170-25-022196 · ownership.xml · derivative · entry 3

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,063

Underlying: Common Stock · 14,687 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000950170-25-022196 · ownership.xml · nonDerivative · entry 1

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,350

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

SEC source: 0000950170-25-022200 · ownership.xml · derivative · entry 3

Cumbo Alexander · CIK 0001685994 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 90,094

Underlying: Common Stock · 30,301 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000950170-25-022200 · ownership.xml · nonDerivative · entry 1

Cumbo Alexander · CIK 0001685994 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,082

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

SEC source: 0000950170-25-017977 · ownership.xml · derivative · entry 1

Ganot Ilan · CIK 0001727460 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Wife

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F2 · derivative.exercise_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F2 · derivative.expiration_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000950170-25-017979 · ownership.xml · derivative · entry 1

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,500

Underlying: Common Stock · 110,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F2 · derivative.exercise_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F2 · derivative.expiration_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000950170-25-017978 · ownership.xml · derivative · entry 2

Herzich Paul · CIK 0001954991 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,700

Underlying: Common Stock · 98,700 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000950170-25-017974 · ownership.xml · derivative · entry 1

Tan Kevin · CIK 0001884056 · CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,300

Underlying: Common Stock · 132,300 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F2 · derivative.exercise_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F2 · derivative.expiration_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000950170-25-017962 · ownership.xml · derivative · entry 1

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,100

Underlying: Common Stock · 169,100 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F2 · derivative.exercise_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F2 · derivative.expiration_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000950170-25-017971 · ownership.xml · derivative · entry 2

Brooks Gabriel · CIK 0001997809 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,900

Underlying: Common Stock · 112,900 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000950170-25-017959 · ownership.xml · derivative · entry 2

Cumbo Alexander · CIK 0001685994 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 401,600

Underlying: Common Stock · 401,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000950170-25-010625 · ownership.xml · nonDerivative · entry 2

Ganot Ilan · CIK 0001727460 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Wife

Disclosed balance after: 11,689

F2 · kind: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot.

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot.

SEC source: 0000950170-25-010625 · ownership.xml · derivative · entry 6

Ganot Ilan · CIK 0001727460 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,884

Underlying: Common Stock · 3,883 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F6 · derivative.exercise_date: On the Grant Date, the reporting person was granted 15,533 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date.

F6 · derivative.expiration_date: On the Grant Date, the reporting person was granted 15,533 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date.

SEC source: 0000950170-25-010625 · ownership.xml · derivative · entry 5

Ganot Ilan · CIK 0001727460 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Wife

Disclosed balance after: 389

Underlying: Common Stock · 388 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F5 · derivative.exercise_date: On January 27, 2022 (the "Grant Date") Ms. Ganot was granted 1,553 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date.

F5 · derivative.expiration_date: On January 27, 2022 (the "Grant Date") Ms. Ganot was granted 1,553 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date.

SEC source: 0000950170-25-010625 · ownership.xml · nonDerivative · entry 3

Ganot Ilan · CIK 0001727460 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,690

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · ownership.direct: Represents 94,648 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship.

SEC source: 0000950170-25-010625 · ownership.xml · nonDerivative · entry 1

Ganot Ilan · CIK 0001727460 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Wife

Disclosed balance after: 11,833

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000950170-25-004971 · ownership.xml · nonDerivative · entry 2

Tan Kevin · CIK 0001884056 · CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,789

F3 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The sales do not represent a discretionary trade by Mr. Tan.

F2 · balance_after: Includes 4,152 and 4,152 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2024 and November 29, 2024, respectively.

SEC source: 0000950170-25-004971 · ownership.xml · derivative · entry 3

Tan Kevin · CIK 0001884056 · CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 11,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units were granted on January 9, 2023 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F4 · derivative.expiration_date: The restricted stock units were granted on January 9, 2023 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000950170-25-004971 · ownership.xml · nonDerivative · entry 1

Tan Kevin · CIK 0001884056 · CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,862

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert to common stock on a one-for-one basis.

F2 · balance_after: Includes 4,152 and 4,152 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2024 and November 29, 2024, respectively.

SEC source: 0000950170-25-003054 · ownership.xml · nonDerivative · entry 2

Ganot Ilan · CIK 0001727460 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Wife

Disclosed balance after: 11,445

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The sales do not represent a discretionary trade by Ms. Ganot.

SEC source: 0000950170-25-003052 · ownership.xml · derivative · entry 4

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,293

Underlying: Common Stock · 18,293 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "Smith RSUs").

F3 · derivative.exercise_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 6, 2025 ("the Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Second Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.

F3 · derivative.expiration_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 6, 2025 ("the Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Second Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.